Pages
- About Us
- Adam Boxer, M.D., Ph.D.
- Bradley T. Hyman, M.D., Ph.D.
- David Brazier
- David H. P. King
- David R. Elmaleh, Ph.D.
- Eran Segal, Ph.D.
- George Alex
- George D. Behrakis
- Gillian Sandler
- Isabelle Bajeux-Besnainou
- Joseph B. Kelley
- Karen R. Reeves, M.D.
- Keith A. Johnson, M.D.
- Keith Greenfield
- Marc de Garidel
- Martin R. Farlow, M.D.
- Matthew Ebert
- Megan Levings, Ph.D.
- Michael E. Porter
- Noah Gottdiener
- Peter Conti, M.D., Ph.D.
- Philip Ashton-Rickardt, Ph.D.
- Robert C. Malenka, M.D., Ph.D.
- Ronald G. Tompkins, M.D., Sc.D.
- Rudolph E. Tanzi, Ph.D.
- Sangram S. Sisodia, Ph.D.
- Scott E. Kasner, M.D.
- Seth Paul Finklestein, M.D.
- Shahin Tabatabaei, M.D.
- Steven L. Wagner, Ph.D.
- Thierry Porté
- Vijay Kuchroo, D.V.M., Ph.D.
- William S. Belichick
- Ziv Neeman, M.D.
- AZTherapies – Home
- Careers
- Contact
- News
- Our Science
- Pipeline
- Site Map
- Terms of Use/Privacy Policy
Posts by category
- Category: Events
- Category: News
- Category: Press Releases
- AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021
- AZTherapies Announces Leadership Transition, Appointing Marc de Garidel Chief Executive Officer and Member of the Board of Directors
- AZTherapies Announces Closing of $33.6 Million Series C-1 Financing Building Upon Recent $37.5 Million Series C Financing
- AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS)
- AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board
- AZTherapies Strengthens Board of Directors & Business Advisory Board with New Appointments
- VIDEO – COO & CBO Jay Mohr Provides Corporate Overview in Proactive Research Interview
- AZTherapies to Present at 22nd Annual BIO CEO & Investor Conference
- AZTherapies Announces Publication of Data Supporting the Targeting of Neuroinflammation in the Treatment of ALS in Scientific Reports
- AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
- AZTherapies Strengthens Neuroinflammation-Targeted Pipeline Through Acquisition of Smith Therapeutics
- AZTherapies Closes $26.3 Million Series C Preferred Equity Financing
- New Alzheimer’s research offers hope to reduce the disease’s effects
- AZTherapies Announces Appointment of Pharma Industry Veteran George D. Behrakis to its Board of Directors
- AZTherapies Completes Enrollment in COGNITE Pivotal Phase 3 Trial of ALZT-OP1 for the Treatment of Early Alzheimer’s Disease
- Jay Mohr Joins AZTherapies as Chief Operating & Business Officer and Head of Commercial Development
- AZTherapies to Present at Maxim Group’s Conference on Alzheimer’s Disease